Spruce Biosciences, Inc. SPRB
Set alert
44.55 USD -1.84 -3.97%
At close · Nov 2
44.55 0.00 0.00%
After hours · Nov 2, 4:00 PM ET
43.78 Day range 46.99
38.06 52-week range 129.00
- YTD
- -48.86%
- 1 year
- -59.54%
- Open
- 46.40
- Prev close
- 46.39
- Mkt cap
- 128.04M
- Vol
- 90.54K
- Avg vol
- 82.43K
- EPS
- -39.12
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 43.78
- High
- 46.99
- Forward P/E
- -0.41
- Beta
- 0.00
- Short ratio
- 0.10
- Inst. own
- 46.69%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 12, 2024
- 50-d avg
- 0.50446
- 200-d avg
- 0.668845
- 1y target
- 1.83
1D chart
Signals (10)
| Name | Time | Ago |
|---|---|---|
| SMA: Bullish | 3:59 PM | 16 hours ago |
| SMA: Bullish | 3:59 PM | 16 hours ago |
| SMA: Bearish | 3:56 PM | 16 hours ago |
| SMA: Bullish | 3:48 PM | 16 hours ago |
| MACD: Buy Signal | 2:19 PM | 18 hours ago |
| MACD: Sell Signal | 2:06 PM | 18 hours ago |
| SMA: Bearish | 1:49 PM | 18 hours ago |
| SMA: Bullish | 1:47 PM | 18 hours ago |
| MACD: Buy Signal | 1:47 PM | 18 hours ago |
| RSI: Oversold | 1:41 PM | 18 hours ago |
Analyst view
Consensus: hold
Hold
Price target (mean) 1.83 -95.9% downside
Now 44.55
- Target (low)
- 1.00
- Target (mean)
- 1.83
- Target (high)
- 3.00
Ratings (0m) 5 0 buy · 5 hold · 0 sell
- Strong buy0
- Buy0
- Hold5
- Sell0
- Strong sell0
Recommendation trend
- This month 5
- 1 month ago 5
- 2 months ago 5
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.205 | -0.25 – -0.16 | -0.23 | +10.9% | 885.00K | -69.3% | 4 |
| Next quarter | -0.19667 | -0.22 – -0.17 | -0.28 | +29.8% | 500.00K | -75.0% | 3 |
| Current year | -0.93 | -0.99 – -0.87 | -1.24 | +25.0% | 5.09M | -49.5% | 4 |
| Next year | -0.6375 | -0.92 – -0.27 | -0.93 | +31.4% | 1.60M | -68.6% | 4 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 16, 2024 | HC Wainwright & Co. | Reiterated | Neutral | Neutral |
| Dec 12, 2024 | Guggenheim | Reiterated | Neutral | Neutral |
| Dec 11, 2024 | JMP Securities | Downgrade | Market Outperform | Market Perform |
| Dec 11, 2024 | RBC Capital | Reiterated | Sector Perform | Sector Perform |
| Dec 11, 2024 | Oppenheimer | Downgrade | Outperform | Perform |
| Nov 12, 2024 | RBC Capital | Reiterated | Sector Perform | Sector Perform |
| Aug 19, 2024 | HC Wainwright & Co. | Reiterated | — | Neutral |
| Aug 13, 2024 | RBC Capital | Reiterated | Sector Perform | Sector Perform |
| Jun 13, 2024 | Oppenheimer | Maintained | Outperform | Outperform |
| Jun 5, 2024 | HC Wainwright & Co. | Reiterated | — | Neutral |
| May 14, 2024 | HC Wainwright & Co. | Reiterated | — | Neutral |
| Mar 14, 2024 | RBC Capital | Downgrade | Outperform | Sector Perform |
| Mar 14, 2024 | HC Wainwright & Co. | Downgrade | Buy | Neutral |
| Mar 14, 2024 | Leerink Partners | Downgrade | Outperform | Market Perform |
| Mar 14, 2024 | JMP Securities | Maintained | Market Outperform | Market Outperform |
| Mar 14, 2024 | Ladenburg Thalmann | Downgrade | Buy | Neutral |
| Mar 14, 2024 | Guggenheim | Downgrade | Buy | Neutral |
| Mar 5, 2024 | RBC Capital | Reiterated | Outperform | Outperform |
| Feb 26, 2024 | RBC Capital | Maintained | Outperform | Outperform |
| Feb 21, 2024 | Guggenheim | Initiated | — | Buy |
| Nov 20, 2023 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Sep 13, 2023 | RBC Capital | Reiterated | Outperform | Outperform |
| Sep 13, 2023 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Sep 8, 2023 | SVB Leerink | Upgrade | Market Perform | Outperform |
| Aug 18, 2023 | Oppenheimer | Maintained | Outperform | Outperform |
| Aug 18, 2023 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Aug 16, 2023 | JMP Securities | Maintained | Outperform | Outperform |
| Aug 15, 2023 | RBC Capital | Reiterated | Outperform | Outperform |
| Jun 13, 2023 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| May 23, 2023 | Oppenheimer | Reiterated | Outperform | Outperform |